Moderate to severe hidradenitis suppurativa
Conditions
Brief summary
Proportion of patients achieving clinical response evaluated by the simplified Hidradenitis Suppurativa Clinical Response (HiSCR) after 16 weeks of treatment
Detailed description
Number and severity of adverse events, Physical examination, vital signs, safety laboratory measurements, ECGs
Interventions
DRUGVAY736
DRUGPlacebo Solution for injection or infusion 0 mg/1 mL
Sponsors
Novartis Pharma AG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients achieving clinical response evaluated by the simplified Hidradenitis Suppurativa Clinical Response (HiSCR) after 16 weeks of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Number and severity of adverse events, Physical examination, vital signs, safety laboratory measurements, ECGs | — |
Countries
Austria, Belgium, France, Germany, Hungary, Spain
Outcome results
None listed